Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Based on a preliminary analysis by AstraZeneca, Baltimore County, together with the city of Baltimore, ranks in the top counties in the U.S. for lung cancer risk.

Bad training, poor sanitation and improper procedures were among the numerous problems at Baltimore’s Emergent plant that ruined 400 million vaccine doses in all, according to a House panel report.

AstraZeneca shares were trading about 3% higher at 8.62 pounds ($11.68) on the London Stock Exchange on Thursday morning. Stay connected with the most up-to-date coverage of the stories that matter.

Around 30 million to 50 million doses of Johnson & Johnson's JNJ COVID-19 vaccine manufactured earlier this year sit idle in Emergent BioSolutions Inc's EBS Baltimore plant, Reuters reported ...

The U.S. Food and Drug Administration said on Friday certain lots of AstraZeneca's COVID-19 vaccine manufactured at a problem-plagued Baltimore facility are fit to be shipped outside the United ...

The Baltimore plant belonging to Emergent BioSolutions Inc was producing vaccines for both AstraZeneca Plc and Johnson & Johnson under a $628 million U.S. government contract.

Lawmakers are expanding their probe of the troubled Emergent BioSolutions vaccine plant in Baltimore and are now focusing attention on manufacturing contracts with AstraZeneca and Johnson ...

Federal officials stripped Emergent of its control of the Baltimore facility back in April, putting Johnson & Johnson in charge and telling AstraZeneca to find another manufacturer.

Employees work in a lab at Emergent Biosolutions, which is manufacturing vaccines for AstraZeneca and Johnson Johnson, on Feb, 8, 2021 in Baltimore, Md. Michael Robinson Chavez / The Washington ...